CY1120281T1 - Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail - Google Patents

Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail

Info

Publication number
CY1120281T1
CY1120281T1 CY20181100568T CY181100568T CY1120281T1 CY 1120281 T1 CY1120281 T1 CY 1120281T1 CY 20181100568 T CY20181100568 T CY 20181100568T CY 181100568 T CY181100568 T CY 181100568T CY 1120281 T1 CY1120281 T1 CY 1120281T1
Authority
CY
Cyprus
Prior art keywords
trail
single chain
receptor agonist
chain proteins
trail receptors
Prior art date
Application number
CY20181100568T
Other languages
Greek (el)
English (en)
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Fritz G. BUCHANAN
Darren C. PHILLIPS
Susan E. LAPPE
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of CY1120281T1 publication Critical patent/CY1120281T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
CY20181100568T 2014-04-23 2018-05-25 Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail CY1120281T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Publications (1)

Publication Number Publication Date
CY1120281T1 true CY1120281T1 (el) 2019-07-10

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100568T CY1120281T1 (el) 2014-04-23 2018-05-25 Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail

Country Status (38)

Country Link
US (5) US9908927B2 (enExample)
EP (2) EP3134430B1 (enExample)
JP (2) JP6523331B2 (enExample)
KR (2) KR20190135546A (enExample)
CN (2) CN111718424A (enExample)
AR (1) AR100168A1 (enExample)
AU (3) AU2015249649B2 (enExample)
BR (1) BR112016024515B1 (enExample)
CA (2) CA3184067A1 (enExample)
CL (1) CL2016002683A1 (enExample)
CR (1) CR20160516A (enExample)
CY (1) CY1120281T1 (enExample)
DK (1) DK3134430T3 (enExample)
DO (1) DOP2016000284A (enExample)
EC (1) ECSP16089579A (enExample)
ES (1) ES2672368T3 (enExample)
HR (1) HRP20180950T1 (enExample)
HU (1) HUE038914T2 (enExample)
IL (2) IL248244B (enExample)
LT (1) LT3134430T (enExample)
MA (2) MA45069A (enExample)
MX (2) MX2016013858A (enExample)
MY (1) MY181986A (enExample)
NO (1) NO2776305T3 (enExample)
PE (1) PE20170299A1 (enExample)
PH (2) PH12020500377A1 (enExample)
PL (1) PL3134430T3 (enExample)
PT (1) PT3134430T (enExample)
RS (1) RS57153B1 (enExample)
RU (1) RU2699285C2 (enExample)
SG (3) SG10202111785VA (enExample)
SI (1) SI3134430T1 (enExample)
SM (1) SMT201800286T1 (enExample)
TR (1) TR201806912T4 (enExample)
TW (2) TWI747178B (enExample)
UA (1) UA118286C2 (enExample)
UY (1) UY36095A (enExample)
WO (1) WO2015164588A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738831B2 (ja) * 2015-05-04 2020-08-12 アポジェニックス アーゲー 単鎖ｃｄ４０受容体アゴニストタンパク質
CN108430492B (zh) 2015-10-23 2022-05-03 阿珀吉科吉尼科斯股份公司 单链cd27受体激动剂蛋白
AU2016342420B2 (en) 2015-10-23 2020-10-01 Apogenix Ag Single-chain LIGHT receptor agonist proteins
WO2017068185A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
CN109153711B (zh) * 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
MX2018011219A (es) * 2016-03-16 2019-01-10 Merrimack Pharmaceuticals Inc Trail diseñado por ingenieria para terapia de cancer.
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20190017804A (ko) * 2016-06-13 2019-02-20 메리맥 파마슈티컬즈, 인크. 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CN111050784B (zh) * 2017-08-11 2024-03-19 伊利诺伊大学理事会 截短的豚鼠l-天冬酰胺酶变体及其使用方法
TW202003553A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
US20230212260A1 (en) 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
AU2022281108A1 (en) 2021-05-28 2023-12-14 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7538088B2 (en) 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
MX2007010484A (es) 2005-04-15 2007-10-15 Rappaport Family Inst For Res Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CA2963124C (en) 2007-07-10 2019-10-15 Apogenix Ag Tnf superfamily collectin fusion proteins
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PL2310509T3 (pl) * 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
JP2012502994A (ja) * 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
WO2010042890A2 (en) * 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
AU2010206681A1 (en) * 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
AU2010334974A1 (en) * 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
AU2011240620A1 (en) * 2010-04-13 2012-10-18 Medimmune, Llc Fibronectin type III domain-based multimeric scaffolds
WO2013092998A1 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
HK1207095A1 (en) 2012-07-18 2016-01-22 阿珀吉尼科斯股份公司 Composition comprising a mixture of cd95-fc isoforms

Also Published As

Publication number Publication date
CN106459221B (zh) 2020-09-01
NO2776305T3 (enExample) 2018-01-27
CN111718424A (zh) 2020-09-29
AU2015249649A1 (en) 2016-11-10
ES2672368T3 (es) 2018-06-14
MX2019013587A (es) 2020-01-13
RU2016145608A (ru) 2018-05-28
JP6714751B2 (ja) 2020-06-24
IL248244A0 (en) 2016-11-30
TW202024123A (zh) 2020-07-01
DOP2016000284A (es) 2017-02-15
PH12020500377A1 (en) 2022-11-14
IL272612A (en) 2020-03-31
DK3134430T3 (en) 2018-05-22
NZ725476A (en) 2023-09-29
PH12016502079B1 (en) 2016-12-19
AU2020202247A1 (en) 2020-04-23
MY181986A (en) 2021-01-18
KR20190135546A (ko) 2019-12-06
SG10201806465TA (en) 2018-08-30
EP3134430A1 (en) 2017-03-01
MX2016013858A (es) 2017-08-02
RU2699285C2 (ru) 2019-09-04
IL248244B (en) 2020-03-31
UA118286C2 (uk) 2018-12-26
UY36095A (es) 2015-10-30
HRP20180950T1 (hr) 2018-08-10
US20150337027A1 (en) 2015-11-26
PT3134430T (pt) 2018-04-20
TWI683825B (zh) 2020-02-01
KR20170012257A (ko) 2017-02-02
TWI747178B (zh) 2021-11-21
LT3134430T (lt) 2018-05-10
US20210040178A1 (en) 2021-02-11
AU2018271369B2 (en) 2020-01-02
JP2017513503A (ja) 2017-06-01
TR201806912T4 (tr) 2018-06-21
CN106459221A (zh) 2017-02-22
PL3134430T3 (pl) 2018-08-31
ECSP16089579A (es) 2018-05-31
SMT201800286T1 (it) 2018-07-17
US20240174731A1 (en) 2024-05-30
JP6523331B2 (ja) 2019-05-29
HUE038914T2 (hu) 2018-12-28
EP3134430B1 (en) 2018-03-21
CA2946402C (en) 2023-02-28
CA2946402A1 (en) 2015-10-29
SG11201608767XA (en) 2016-11-29
CA3184067A1 (en) 2015-10-29
CR20160516A (es) 2017-05-10
SG10202111785VA (en) 2021-12-30
MA45069A (fr) 2019-04-03
US20250145688A1 (en) 2025-05-08
EP3366699A1 (en) 2018-08-29
AU2015249649B2 (en) 2018-10-04
JP2019162114A (ja) 2019-09-26
KR102079919B1 (ko) 2020-02-24
RS57153B1 (sr) 2018-07-31
TW201620928A (zh) 2016-06-16
CL2016002683A1 (es) 2017-07-07
MA39770A (fr) 2015-10-29
SI3134430T1 (en) 2018-05-31
RU2016145608A3 (enExample) 2018-12-26
US9908927B2 (en) 2018-03-06
BR112016024515A2 (pt) 2017-10-10
WO2015164588A1 (en) 2015-10-29
AR100168A1 (es) 2016-09-14
US20180222962A1 (en) 2018-08-09
BR112016024515B1 (pt) 2020-03-31
PH12016502079A1 (en) 2016-12-19
AU2018271369A1 (en) 2018-12-20
PE20170299A1 (es) 2017-05-06

Similar Documents

Publication Publication Date Title
CY1120281T1 (el) Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
CY1122188T1 (el) Θεραπευτικη αντιμετωπιση της προοδευτικης οστεοποιους ινοδυσπλασιας
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
EP3604337A4 (en) B7-H3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THE SAME, AND ITS MEDICAL USE
CY1121539T1 (el) Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
CY1124360T1 (el) Αντισωματα aντι-il-33 και χρησεις αυτων
MX2020000960A (es) Anticuerpos anti-tigit.
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
IL258448B1 (en) Antigen-binding proteins that activate the leptin receptor
DK3293202T3 (da) Anti human interleukin-1 receptor accessory protein (il1rap) antibodies and uses thereof
CY1122132T1 (el) Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
MX2017014140A (es) Proteinas agonistas receptoras cd40 de cadena simple.
MX2015016304A (es) Proteinas de union al antigeno del receptor de oncostatina m.
EP3757133A4 (en) ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE
IL279780A (en) Compositions and methods for agonizing the cb2 receptor
EP3634466A4 (en) MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1